Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Exosomal miR-126 as a circulating biomarker in non-small-cell lung cancer regulating cancer progression

F Grimolizzi, F Monaco, F Leoni, M Bracci, S Staffolani, C Bersaglieri, S Gaetani, M Valentino, M Amati, C Rubini, F Saccucci, J Neuzil, M Tomasetti, L Santarelli

. 2017 ; 7 (1) : 15277.

Jazyk angličtina Země Velká Británie

Perzistentní odkaz   https://www.medvik.cz/link/bmc22006737

Grantová podpora
NV16-31604A MZ0 CEP - Centrální evidence projektů

Lung cancer is one of the leading causes of cancer-related deaths. It is diagnosed mostly at the locally advanced or metastatic stage. Recently, micro RNAs (miRs) and their distribution in circulation have been implicated in physiological and pathological processes. In this study, miR-126 was evaluated in serum, exosome and exosome-free serum fractions in non-small cell lung cancer (NSCLC) patients at early and advanced stages, and compared with healthy controls. Down-regulation of miR-126 was found in serum of advanced stage NSCLC patients. In healthy controls, circulating miR-126 was equally distributed between exosomes and exosome-free serum fractions. Conversely, in both early and advanced stage NSCLC patients, miR-126 was mainly present in exosomes. Different fractions of miR-126 in circulation may reflect different conditions during tumour formation. Incubation of exosomes from early and advanced NSCLC patients induced blood vessel formation and malignant transformation in human bronchial epithelial cells. On the other hand, exosome-enriched miR-126 from normal endothelial cells inhibited cell growth and induces loss of malignancy of NSCLC cells. These findings suggest a role of exo-miRs in the modulation of the NSCLC microenvironmental niche. Exosome-delivered miRs thus hold a substantial promise as a diagnostics biomarker as well as a personalized therapeutic modality.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22006737
003      
CZ-PrNML
005      
20220404160941.0
007      
ta
008      
220216s2017 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1038/s41598-017-15475-6 $2 doi
035    __
$a (PubMed)29127370
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Grimolizzi F $u Grimolizzi, Franco. Department of Clinical Sciences, Section of Biochemistry, Biology and Physics, Via Tronto 10/a, 60020, Ancona, Italy.
245    10
$a Exosomal miR-126 as a circulating biomarker in non-small-cell lung cancer regulating cancer progression / $c F Grimolizzi, F Monaco, F Leoni, M Bracci, S Staffolani, C Bersaglieri, S Gaetani, M Valentino, M Amati, C Rubini, F Saccucci, J Neuzil, M Tomasetti, L Santarelli
520    9_
$a Lung cancer is one of the leading causes of cancer-related deaths. It is diagnosed mostly at the locally advanced or metastatic stage. Recently, micro RNAs (miRs) and their distribution in circulation have been implicated in physiological and pathological processes. In this study, miR-126 was evaluated in serum, exosome and exosome-free serum fractions in non-small cell lung cancer (NSCLC) patients at early and advanced stages, and compared with healthy controls. Down-regulation of miR-126 was found in serum of advanced stage NSCLC patients. In healthy controls, circulating miR-126 was equally distributed between exosomes and exosome-free serum fractions. Conversely, in both early and advanced stage NSCLC patients, miR-126 was mainly present in exosomes. Different fractions of miR-126 in circulation may reflect different conditions during tumour formation. Incubation of exosomes from early and advanced NSCLC patients induced blood vessel formation and malignant transformation in human bronchial epithelial cells. On the other hand, exosome-enriched miR-126 from normal endothelial cells inhibited cell growth and induces loss of malignancy of NSCLC cells. These findings suggest a role of exo-miRs in the modulation of the NSCLC microenvironmental niche. Exosome-delivered miRs thus hold a substantial promise as a diagnostics biomarker as well as a personalized therapeutic modality.
650    07
$a dospělí $7 D000328 $2 czmesh
650    07
$a senioři $7 D000368 $2 czmesh
650    07
$a senioři nad 80 let $7 D000369 $2 czmesh
650    17
$a nádorové biomarkery $x krev $7 D014408 $2 czmesh
650    17
$a nemalobuněčný karcinom plic $x krev $x patologie $7 D002289 $2 czmesh
650    17
$a cirkulující mikroRNA $x krev $7 D000074166 $2 czmesh
650    17
$a exozómy $x metabolismus $x patologie $7 D055354 $2 czmesh
650    07
$a ženské pohlaví $7 D005260 $2 czmesh
650    07
$a lidé $7 D006801 $2 czmesh
650    17
$a nádory plic $x krev $x patologie $7 D008175 $2 czmesh
650    07
$a mužské pohlaví $7 D008297 $2 czmesh
650    17
$a mikro RNA $x krev $7 D035683 $2 czmesh
650    07
$a lidé středního věku $7 D008875 $2 czmesh
650    17
$a RNA nádorová $x krev $7 D012334 $2 czmesh
650    07
$a nádorové mikroprostředí $7 D059016 $2 czmesh
700    1_
$a Monaco, Frederica
700    1_
$a Leoni, Francesca
700    1_
$a Bracci, Massimo
700    1_
$a Staffolani, Sara
700    1_
$a Bersaglieri, Cristiana
700    1_
$a Gaetani, Simona
700    1_
$a Valentino, Matteo
700    1_
$a Amati, Monica
700    1_
$a Rubini, Corrado
700    1_
$a Saccucci, Franca
700    1_
$a Neužil, Jiří, $d 1958- $7 xx0115772
700    1_
$a Tomasetti, Marcp
700    1_
$a Santarelli, Lory
773    0_
$t Scientific Reports $g Roč. 7, č. 1 (2017), s. 15277 $p Sci. rep. $x 2045-2322 $w MED00182195
773    0_
$p Sci. rep. $g 7(1):15277, 2017 11 10
910    __
$a ABA008 $y p $b sig $z 0
990    __
$a 20220216131508 $b ABA008
991    __
$a 20220404160938 $b ABA008
999    __
$a ok $b bmc $g 1760721 $s 1157909
BAS    __
$a 3
BMC    __
$a 2017 $b 7 $c 1 $d 15277 $x MED00182195 $i 2045-2322 $m Scientific reports
GRA    __
$a NV16-31604A $p MZ0
LZP    __
$a 2021-granty

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...